Providing Consultative DMPK Solutions Bridging Drug Discovery and Development
21 Nov 2013

XenoTech and XenoGesis work together to facilitate outsourced drug metabolism and pharmacokinetics (DMPK) studies from early stage drug discovery through development and beyond. The partnership was developed to help mitigate the risk and cost associated with clinical failure. Efficacy and safety are now the leading causes of attrition and are linked to drug exposure in target and off-target tissues. While pharmacokinetics is no longer the leading cause of failure, a drug’s exposure is driven by its pharmacokinetic properties and ultimately remains critical for successful pharmacodynamics and safety. This webinar will showcase the consultative basis of the DMPK CRO alliance and highlight the capabilities with real-life examples of our unique combination of expertise.

Xenotech LLC



Show    per page
1 of 9 Page     1 2 3  ... Next 
Reprogramming of Somatic Cells to Pluripotency Under Low O2 Conditions20 Nov 2014Read
Issues of Color in Histology in Medicine20 Nov 2014Read
Instrument performance verification in laser diffraction11 Nov 2014Read
From Daltons to Megadaltons on a Single Mass Spectrometry Platform: UHR-qTOF for Biopharmaceuticals Analysis11 Nov 2014Read
Powering power plants with online particle size analysis11 Nov 2014Read
How to characterize and optimize inkjet inks - Part 111 Nov 2014Read
How to characterize and optimize inkjet inks Part 211 Nov 2014Read
Pharmaceuticals - When size is not enough11 Nov 2014Read
Exploring the role of SEC-MALS in protein and polymer characterization11 Nov 2014Read
Clinical Research of Complex Congenital Brain Malformations by Combined Neuroimaging and Massively Parallel Sequencing Using the TruSight One Sequencing Panel6 Nov 2014Read